Core Viewpoint - The company reported a loss of approximately 166 million yuan for the first half of 2025, which is a decrease of 7.8% year-on-year, indicating an improvement in financial performance despite ongoing losses [1] Financial Performance - Research and development costs amounted to approximately 132 million yuan, reflecting a year-on-year increase of 56.9% [1] - The loss per share was reported at 1.06 yuan [1] Reasons for Cost Increase - The increase in R&D costs is primarily attributed to: - Increased milestone expenditures related to the CMC development, particularly in preparation for the submission of the Biologics License Application (BLA) for LBL-024 [1] - Higher clinical development expenses due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034 [1]
维立志博-B公布中期业绩 净亏损约1.66亿元 同比减少7.8%